Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PAILOT
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 19 May 2015 Planned End Date changed from 1 Jul 2018 to 1 Jan 2019 as reported by ClinicalTrials.gov record.